关注投资家，⭐，您会收到最新推送 作者 | 投资哥 百达信生物完成Pre-A轮融资，专注于创新疫苗佐剂研发与生产 近日，专注于创新疫苗佐剂开发与产业化的生物技术公司——重庆百达信生物技术有限公司近日宣布， 已成功完成超过3000万元人民币的Pre-A轮融资。本轮融资由领航新界资本领投。本轮所募资金将主要 用于加速公司化学合成QS-21等佐剂原料的GMP生产基地建设，推动在全球范围内的商业化进程，并进 一步拓展公司在新型佐剂领域的研发管线。（动脉网） 迈锐迪完成数千万元天使轮融资，赋能核药产业转化 近日，聚焦肿瘤与神经领域的创新企业迈锐迪宣布完成数千万元天使轮融资。本轮融资由省科创投院士 基金、西部成果转化中心、咸阳财金、国生创新、迈锐可联合投资。资金将用于精准可控高负载核药项 目开发及放射性药物中试平台建设。迈锐迪由四川大学微流控技术团队与华西医院核医学科专家联合发 起，致力于推动微流控技术在核医药领域的应用与产业化。（DoNews） 来源 | 投资家网 融资 修实生物完成近亿元A轮融资，深耕多肽生物合成领域 近日，修实生物医药（南通）有限公司宣布已完成近亿元A轮融资。本轮融资由老股东华泰紫金领投， 老股东拾 ...

公司将建设放射性药物中试平台，依托微流控技术在放射性药物制备过程的显著优势，为放射性药物研 发团队提供产品概念验证及CRO、CDMO等服务，包括产品概念验证、技术二次开发熟化、生物分 布、质量研究、产品评价以及核素标记等服务。平台将吸引全国乃至全球高校及科研院所核医药科技成 果转化，助力核医药产业发展。 四川省科创投董事长陈庆红表示：核医疗产业正以迅猛之势崛起，成为全球医疗健康领域的焦点。从全 球视角来看，核医疗产业正处于快速发展的黄金时期，治疗性核药已在欧美等国家上市销售，我国也有 多款肿瘤治疗的核药进入临床试验并取得进展。四川迈锐迪医疗科技有限公司是一家依托四川大学微流 控技术团队和四川大学华西医院核医学科专家团队联合发起设立的一家专注核药开发的平台型企业，通 过微流控的平台性技术，给更多的核药提供技术二次开发和成果转化。本次对迈锐迪的投资，既是对核 医疗产业发展方向的认可，更是对高校科技成果转化的持续助力。 迈锐迪医疗总经理刘承红表示：感谢各位投资人对迈锐迪的认可与支持，在当前中国核医药高速发展的 关键时期，投资人的大力支持是迈锐迪前进的重要动力。迈锐迪将依托微流控及微反应器技术搭建核素 分离与纯化技术 ...

Focus Review - The hard technology sector is seeing significant investments, particularly in commercial aerospace, with Beijing Xinghe Power Aerospace Technology Co., Ltd. completing a Series D financing round totaling 2.4 billion yuan [4][13][14]. - The healthcare sector is highlighted by the success of nuclear medicine companies, with Radiant Technology securing $77 million in funding and Chengdu Nureter Medical completing approximately 800 million yuan in Series D financing [5][42][37]. - In the internet sector, AI companies are focusing on cost reduction and efficiency improvements, with Robopoet and Lingjing AI both completing several million yuan in angel financing [6][44][47]. Hard Technology - Beijing Xinghe Power Aerospace completed a Series D financing round of 2.4 billion yuan, with multiple investment firms participating [4][13][14]. - Tianbing Technology announced nearly 2.5 billion yuan in Pre-D and D round financing, supported by various well-known institutions [30]. - Tianqing Aerospace Technology completed over 100 million yuan in Series A financing, with investments from several prominent funds [12]. Healthcare - Radiant Technology raised $77 million, including $50 million in Series C equity financing and $27 million in debt financing [5][37]. - Chengdu Nureter Medical completed approximately 800 million yuan in Series D financing, led by several major investment firms [42]. - Dapu Biotechnology announced the completion of a B2 round financing led by a fund under Shanghai Science and Technology Innovation Group [38]. Internet/Enterprise Services - Robopoet, an AI companion hardware company, completed several million yuan in angel financing led by Sequoia Capital [44]. - Lingjing AI, an AI animation industrialization platform, also secured several million yuan in angel financing [47]. - Source Merchant Technology completed a 5 million yuan angel round investment from Tianjiong Capital [45].

纽瑞特医疗致力于同位素及药物的创新研制、生产和销售 ， 已建立国际 领先的 医用同位素、药物 研发生产和 CDMO服务基地。 公司 通过与国际医药和医疗器械公司开展战略合作，加速前沿放射 性药物的本土化生产和运营 。 纽瑞特医疗布局 了 多款稀缺核素并已初见成效：自主创新的 傢麟 锗镓发生器 不仅在国内市场稳扎 稳打，更成功 "出海"进入东南亚市场，为下一步拓展海外市场奠定基础；建成 中国首台商用 30MeV IKON质子加速器 ， 即将实现锗 [ Ge]、锕[ Ac]等10余种关键核素自主制备与供应 ； 同 时也 布局 了 镭 [ Ra]、铅[ Pb]等热门核素的研发生产 。 纽瑞特医疗有 4条在研管线处于临床阶段：适用于肝癌适应症的NRT6003注射液已进入 Ⅲ 期临床 试验；适用于胰腺癌适应症的 NRT6008注射液正在开展Ⅰ/Ⅱ期临床试验；适用于实体瘤的两款放 射性药物进入Ⅰ期临床试验（在中国和美国均获得临床试验许可）。同时，另有多条研发管线处于临 床前开发阶段。 关键核素自主制备，创新核药临床转化实现突破。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 据 IPO早知道消 ...

Group 1 - Two companies, Xiantong Pharmaceutical and Huaxida, have submitted applications for listing on the Hong Kong Stock Exchange after delisting from the New Third Board, indicating a new wave of companies seeking to transition to the Hong Kong market [1][3] - Xiantong Pharmaceutical is a leader in the nuclear medicine sector, backed by significant capital from Kweichow Moutai Group's Moutai Jinshi Fund, enhancing its strategic positioning for the Hong Kong listing [3] - Huaxida focuses on Android TV smart terminal devices and has established a broad global distribution network, with Tencent holding a 3.13% stake, marking its second attempt at capital raising after failing to list on the Beijing Stock Exchange [3] Group 2 - In 2023, over 10 companies have successfully transitioned from the New Third Board to the Hong Kong Stock Exchange, with an additional 23 companies processing transfer applications, reflecting a trend of companies seeking to capitalize on the Hong Kong market [3][4] - The influx of New Third Board companies to Hong Kong signals a growing demand for larger, more international financing platforms, as the Hong Kong market offers greater liquidity and serves as a strategic launchpad for global operations [4] - The Hong Kong capital market's internationalization, flexible listing regulations, and diverse investor base make it particularly attractive for new economy sectors like biomedicine and technology, providing growth-stage companies with essential financing opportunities [4]